share_log

复旦张江(01349.HK):注射用FZ-AD005抗体偶联剂用于治疗晚期实体瘤I期临床试验完成首例受试者入组

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced completion of enrollment of the first participant in Phase I clinical trial of injectable FZ-AD005 antibody conjugate for the treatment of advanced solid tumors.

Gelonghui Finance ·  Jul 24, 2024 09:08

On July 24th, GLH - Fudan Zhangjiang (01349.HK) announced that the Phase I clinical trial of the injection FZ-AD005 antibody conjugate (anti-DLL3 antibody conjugate BB05) developed by the company for the treatment of advanced solid tumors has recently completed the enrollment of the first subject.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 280

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.